Literature DB >> 16614537

Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.

Chanoch Miodownik1, Vladimir Lerner, Nikolay Statsenko, Tzvi Dwolatzky, Boris Nemets, Elina Berzak, Joseph Bergman.   

Abstract

Treatment strategies against acute neuroleptic-induced akathisia (NIA) include anticholinergic (antimuscarinic) agents, dopamine agonists, GABAergic agents, beta-blockers, benzodiazepines, and serotonin antagonists. However, many patients who have acute akathisia fail to respond. In previous studies, mianserin and vitamin B6 were found to be effective in the treatment of acute akathisia. The purpose of this study was to compare the efficacy of B(6), mianserin and placebo in the treatment of acute NIA. Sixty schizophrenia and schizoaffective inpatients who have NIA were randomly divided to receive vitamin B(6) 1,200 mg/d, mianserin 15 mg/d, or placebo for 5 days, in a double-blind design. The Barnes Akathisia Rating Scale, Brief Psychiatric Rating Scale, and Clinical Global Impression were used to assess the severity of NIA and psychotic symptoms. The assessment was made at baseline and daily for the duration of the study. Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales. The objective subscale did not show significant positive results (P = 0.056), but there was a trend toward symptom amelioration in both groups. A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005). Our results indicate that high doses of B(6) and a low dose of mianserin may be a useful addition to current treatments of NIA. The efficacy of vitamin B(6) and mianserin suggests that the pathophysiology of acute NIA is heterogeneous with the various subtypes of acute NIA responding differently to the various pharmacological approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614537     DOI: 10.1097/00002826-200603000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  9 in total

1.  High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.

Authors:  Musa U Umar; Aliyu A Isa; Asmaul H Abba
Journal:  Ther Adv Psychopharmacol       Date:  2015-12-14

2.  Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis.

Authors:  Yukiko Tomioka; Shusuke Numata; Makoto Kinoshita; Hidehiro Umehara; Shin-Ya Watanabe; Masahito Nakataki; Yoshimi Iwayama; Tomoko Toyota; Masashi Ikeda; Hidenaga Yamamori; Shinji Shimodera; Atsushi Tajima; Ryota Hashimoto; Nakao Iwata; Takeo Yoshikawa; Tetsuro Ohmori
Journal:  J Psychiatry Neurosci       Date:  2018-05       Impact factor: 6.186

3.  Emergency treatment of movement disorders.

Authors:  Shu-Ching Hu; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

5.  The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Authors:  Tamara Pringsheim; David Gardner; Donald Addington; Davide Martino; Francesca Morgante; Lucia Ricciardi; Norman Poole; Gary Remington; Mark Edwards; Alan Carson; Thomas R E Barnes
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

Review 6.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-22       Impact factor: 2.570

Review 8.  Vitamin B6: a long known compound of surprising complexity.

Authors:  Sutton Mooney; Jan-Erik Leuendorf; Christopher Hendrickson; Hanjo Hellmann
Journal:  Molecules       Date:  2009-01-12       Impact factor: 4.411

9.  Natural Medicines for Psychotic Disorders: A Systematic Review.

Authors:  H J Rogier Hoenders; Agna A Bartels-Velthuis; Nina K Vollbehr; Richard Bruggeman; Henderikus Knegtering; Joop T V M de Jong
Journal:  J Nerv Ment Dis       Date:  2018-02       Impact factor: 2.254

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.